RESPIRATORY DRUG DELIVERY FORMULATION MARKET ANALYSIS

Respiratory Drug Delivery Formulation Market, by Formulation Type (Solution Aerosol, Suspension Aerosol, and Dry Powder), by Device Type (Metered Dose Inhaler, Dry Powder Inhaler, and Nebulizers), by Canister Type (Plain Canister and Coated Canister), by Application (Chronic Obstructive Pulmonary Disease, Asthma, and Cystic Fibrosis, Others), by End Users (Hospitals and Clinics, and Homecare), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI2649
Formats :
Excel and PDF
Industry : Medical Devices

Leading Companies

Respiratory drug delivery formulation Market- Competitive Analysis

Manufacturers are focused on development, manufacturing, and marketing of multisource and branded pharmaceuticals, thereby augmenting the market growth. For instance, in November 2017, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) approved Fasenra (benralizumab) for the treatment of patients with severe asthma, aged 12 years and older.

Key players operating in the global respiratory drug delivery formulation market include Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, 3M, AstraZeneca plc, Merck and Co., Inc., Omron Corporation, Novartis AG, Boehringer Ingelheim GmbH, Sunovion Pharmaceuticals Inc., Hovione, Catalent Pharma Solutions, and Aphios Corporation.

RESPIRATORY DRUG DELIVERY FORMULATION MARKET ANALYSIS

Leading Companies

Respiratory Drug Delivery Formulation Market Report Snapshots

EXISTING CLIENTELE